Key to our unified synthetic strategy is the use of a
common methoxypyridine intermediate (see 4, Scheme 1).
followed by reduction of the vinylogous ester of the adduct
and acidic workup to give 6 in 63% yield over the two steps.
Intramolecular Heck reaction of 6 proceeded without event
to afford tricyclic enone 9 in 79% yield. The R-methylation
of enone 9 and subsequent Luche reduction14 proceeded with
excellent diastereocontrol to give 10 in 92% yield. At this
stage, several variants of the Claisen rearrangement were
explored. Ultimately, the Eschenmoser Claisen rearrange-
ment15 utilizing the dimethyl acetal of N,N-dimethylaceta-
mide (DMA-DMA) proved to be most effective, affording
11 in 94% yield. Iodolactonization of 11 yielded fused
lactone 12 in 78% yield.
Scheme 1. Retrosynthetic Analysis of 2
The structure and relative stereochemistry of iodolactone
12 was confirmed by X-ray analysis of a single crystal (see
ORTEP in Scheme 2). With a robust route to tetracycle 12
Scheme 2. Synthesis of Lactone 12
The methoxy group of the methoxypyridine moiety in 4 may
be removed en route to 1,11 demethylated to unveil the
pyridone in 2, or the methoxypyridine may be unraveled at
a late stage to provide 3. This communication describes our
initial studies toward this overall goal, which has culminated
in a concise first total synthesis of lycoposerramine R.
Retrosynthetically, we envisioned the tetracyclic frame-
work of 2 (Scheme 1) arising from a late-stage reductive
amination of ketoaldehyde 4, which is closely related to 1.
Tricycle 4 could in turn derive from enone 5 by exploiting
a stereospecific pericyclic rearrangement to forge the all-
carbon quaternary center. Enone 5 presented several op-
portunities for the diastereocontrolled intallation of the
potentially challenging quaternary center (e.g., oxy-Cope,
Claisen, or 2,3-Wittig rearrangements). In turn, tricycle 5
could be obtained from 6 via an intramolecular Heck
reaction. The potential Heck precursor 6 could arise from a
union of readily available vinylogous ester 7 and dibromide
812 via a Stork-Danheiser sequence.13
Our synthesis commenced with the coupling of the enolate
of vinylogous ester 7 and picolinyl bromide 8. This was
(5) Larson, K. K.; Sarpong, R. J. Am. Chem. Soc. 2009, 131, 13244–
13245.
secured, we next explored the installation of the piperidine
ring to complete the synthesis of 2. LAH reduction of the
lactone also effected cleavage of the C-I bond leading to
diol 13 (Scheme 3) in 72% yield. Oxidation of 13 under
Swern conditions proceeded without event to yield ketoal-
dehyde 14 in quantitative yield. Two routes for the selective
homologation of the aldehyde group of 14 to afford 4 were
explored (Scheme 4). The first approach entailed selective
Wittig reaction of the aldehyde group using the reagent
derived from methoxymethylene phosphonium chloride,
followed by hydrolysis of the resulting methyl enol ether to
afford 4. Although this reaction worked well on small scale,
the yields proved to be irreproducible on larger scale. After
investigating several alternative homologation strategies, it
(6) This is supported by a comparison of pKa’s of protonated pyridine
and protonated methoxypyridine; see: Joule, J. A.; Mills, K. Heterocyclic
Chemistry, 4th ed.; Blackwell Science Ltd.: Cambridge, 2000; pp 71-
120.
(7) Ishiuchi, K.; Kubota, T.; Morita, H.; Kobayashi, J. Tetrahedron Lett.
2006, 47, 3287–3289.
(8) Katakawa, K.; Kogure, N.; Kitajima, M.; Takayama, H. HelV. Chim.
Acta 2009, 92, 445–452.
(9) Koyama, K.; Morita, H.; Hirasawa, Y.; Yoshinaga, M.; Hoshino,
T.; Obara, Y.; Nakahata, N.; Kobayashi, J. Tetrahedron 2005, 61, 3681–
3690.
(10) Lannotinidine B is especially interesting from a biological perspec-
tive because it has been shown to enhance mRNA expression for nerve
growth factor (NGF) in human glial cells.9
(11) For previous syntheses of 1, see: (a) Staben, S. T.; Kennedy-Smith,
J.; Huang, D.; Corekey, B. K.; LaLonde, R.; Toste, F. D. Angew. Chem.,
Int. Ed. 2006, 45, 5991–5994. (b) DeLorbe, J. E.; Lotz, M. D.; Martin,
S. F. Org. Lett. 2010, 12, 1576–1579.
(12) Kelly, S. A.; Foricher, Y.; Mann, J.; Bentley, J. M. Org. Biomol.
Chem. 2003, 1, 2865–2876.
(14) (a) Luche, J. L. J. Am. Chem. Soc. 1978, 100, 2226–2227. (b)
Molander, G. A. Chem. ReV. 1992, 92, 29–68.
(13) Stork, G.; Danheiser, R. L. J. Org. Chem. 1973, 38, 1775–1776.
2552
Org. Lett., Vol. 12, No. 11, 2010